Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Revenues $ 0 $ 0 $ 0 $ 0
Costs and Expenses        
Operating expenses 297,000 493,000 1,242,000 1,626,000
Research and development expenses 81,000 82,000 308,000 665,000
Loss before other expense (378,000) (575,000) (1,550,000) (2,291,000)
Other expense        
Interest and financing expense (58,000) (413,000) (493,000) (2,437,000)
Net loss $ (436,000) $ (988,000) $ (2,043,000) $ (4,728,000)
Net loss per common share, basic and diluted $ 0.00 $ 0.00 $ (0.01) $ (0.02)
Weighted average common shares outstanding, basic and diluted 319,326,044 298,834,404 315,128,749 298,834,404